We are live on ! Find out more
VTRS icon

Viatris

499 hedge funds and large institutions have $11.7B invested in Viatris in 2018 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 161 increasing their positions, 187 reducing their positions, and 88 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more capital inflows, than outflows

Capital inflows: $1.25B | Capital outflows: $1.2B

0% more call options, than puts

Call options by funds: $166M | Put options by funds: $166M

0.62% less ownership

Funds ownership: 83.76% → 83.14% (-0.62%)

2% less funds holding

Funds holding: 510 → 499 (-11)

14% less repeat investments, than reductions

Existing positions increased: 161 | Existing positions reduced: 187

29% less funds holding in top 10

Funds holding in top 10: 17 → 12 (-5)

31% less first-time investments, than exits

New positions opened: 61 | Existing positions closed: 88

Holders
499
Holders Change
-11
Holders Change %
-2.16%
% of All Funds
11.08%
Holding in Top 10
12
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-29.41%
% of All Funds
0.27%
New
61
Increased
161
Reduced
187
Closed
88
Calls
$166​M
Puts
$166​M
Net Calls
+$184​K
Net Calls Change
+$146​M

VTRS Hedge Fund Activity: Q4 2018 in Review

499 of the 4,504 institutional investors tracked by Wall St. Rank reported a position in Viatris (VTRS) for Q4 2018, worth a combined $11.7B — down 26% from $15.8B a quarter earlier.

Sellers outnumbered buyers: 88 funds closed out of VTRS and 61 opened new positions — a net loss of 27 holders — while 187 trimmed existing stakes and 161 added.

The largest buyer was Goldman Sachs, adding an estimated $126M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $172M sold.

  • 499 institutional investors held Viatris (VTRS) as of Q4 2018, down from 510 in Q3 2018.
  • Funds reported $11.7B of Viatris stock for Q4 2018, down 26% quarter-over-quarter.
  • 61 funds opened new Viatris positions in Q4 2018 and 88 closed out, a net change of -27 holders.
  • The largest Viatris buyer in Q4 2018 was Goldman Sachs, an estimated $126M added.
  • The largest Viatris seller in Q4 2018 was PFM Health Sciences, an estimated $172M sold.

Based on aggregated 13F filings for Q4 2018.